Skip to main content

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model


Endo Health Solutions



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole was unchanged today. By the end of trading, Endo Health Solutions rose 43 cents (1.6%) to $28.04 on average volume. Throughout the day, 2.5 million shares of Endo Health Solutions exchanged hands as compared to its average daily volume of two million shares. The stock ranged in a price between $27.56-$28.32 after having opened the day at $27.58 as compared to the previous trading day's close of $27.61. Other companies within the Drugs industry that increased today were:

MAP Pharmaceuticals



), up 58.6%,

Threshold Pharmaceuticals



), up 19.3%,



TheStreet Recommends


), up 15.4%, and

Keryx Biopharmaceuticals



), up 13.7%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. Endo Health Solutions has a market cap of $3.06 billion and is part of the health care sector. The company has a P/E ratio of 265.8, above the S&P 500 P/E ratio of 17.7. Shares are up 2.2% year to date as of the close of trading on Tuesday. Currently there are nine analysts that rate Endo Health Solutions a buy, one analyst rates it a sell, and nine rate it a hold.

TheStreet Ratings rates Endo Health Solutions as a


. The company's strengths can be seen in multiple areas, such as its increase in net income, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the negative front,

Pacific Biosciences of California



), down 13.9%,

Oxygen Biotherapeutics



), down 13%,

Star Scientific



), down 11.7%, and

Ampio Pharmaceuticals



), down 9.2%, were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE